Bio-Techne Co. (NASDAQ:TECH) Director Amy E. Herr Sells 1,860 Shares

Bio-Techne Co. (NASDAQ:TECH) Director Amy E. Herr sold 1,860 shares of Bio-Techne stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $65.96, for a total transaction of $122,685.60. Following the completion of the transaction, the director now owns 1,976 shares of the company’s stock, valued at $130,336.96. This trade represents a 48.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Bio-Techne Trading Down 0.5 %

NASDAQ TECH opened at $65.49 on Friday. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. Bio-Techne Co. has a 52 week low of $61.16 and a 52 week high of $85.57. The stock has a market capitalization of $10.35 billion, a PE ratio of 66.15, a price-to-earnings-growth ratio of 2.89 and a beta of 1.27. The firm has a 50 day moving average of $72.91 and a two-hundred day moving average of $73.52.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. As a group, research analysts expect that Bio-Techne Co. will post 1.67 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 28th. Stockholders of record on Monday, February 17th will be given a dividend of $0.08 per share. The ex-dividend date is Friday, February 14th. This represents a $0.32 annualized dividend and a dividend yield of 0.49%. Bio-Techne’s dividend payout ratio is presently 32.32%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TECH. Scotiabank lifted their price objective on shares of Bio-Techne from $88.00 to $90.00 and gave the company a “sector outperform” rating in a report on Thursday, February 6th. KeyCorp lifted their price objective on shares of Bio-Techne from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. StockNews.com upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Robert W. Baird cut shares of Bio-Techne from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $88.00 to $68.00 in a report on Wednesday. Finally, Royal Bank of Canada lifted their price objective on shares of Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a report on Thursday, February 6th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Bio-Techne currently has an average rating of “Moderate Buy” and a consensus target price of $84.29.

Institutional Trading of Bio-Techne

Several institutional investors have recently modified their holdings of TECH. Exchange Traded Concepts LLC purchased a new stake in shares of Bio-Techne during the 3rd quarter worth approximately $185,000. Bleakley Financial Group LLC lifted its position in shares of Bio-Techne by 6.0% during the 3rd quarter. Bleakley Financial Group LLC now owns 3,773 shares of the biotechnology company’s stock worth $302,000 after buying an additional 214 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Bio-Techne by 1.8% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 16,347 shares of the biotechnology company’s stock worth $1,307,000 after buying an additional 289 shares during the last quarter. Raymond James & Associates lifted its position in shares of Bio-Techne by 2.4% during the 3rd quarter. Raymond James & Associates now owns 356,597 shares of the biotechnology company’s stock worth $28,503,000 after buying an additional 8,457 shares during the last quarter. Finally, Berry Wealth Group LP lifted its position in shares of Bio-Techne by 15.4% during the 3rd quarter. Berry Wealth Group LP now owns 4,003 shares of the biotechnology company’s stock worth $320,000 after buying an additional 535 shares during the last quarter. Hedge funds and other institutional investors own 98.95% of the company’s stock.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.